Related Experiment Video

Updated: Jun 19, 2026

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors
09:04

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors

Published on: March 15, 2016

Vascular endothelial growth factor pathway-targeted therapy as initial systemic treatment of patients with renal

Elizabeth K Chung1, Walter M Stadler

  • 1Department of Medicine, Section of Hematology/Oncology, The University of Chicago Medical Center, IL 60637-1479, USA.

Clinical Genitourinary Cancer
|November 7, 2009
PubMed

Insights

Advanced renal cancer, often resistant to chemotherapy, now benefits from novel vascular endothelial growth factor (VEGF) inhibitors. These targeted therapies improve survival and quality of life for many patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Advanced renal cancer (kidney cancer) is typically resistant to conventional chemotherapy.
  • Immunotherapy offers limited efficacy in a small patient subset.
  • Understanding the von Hippel-Lindau pathway and angiogenesis is crucial for renal cancer development.

Purpose of the Study:

  • To review clinical trials of vascular endothelial growth factor (VEGF) pathway inhibitors for advanced renal cancer.
  • To provide practical recommendations for established VEGF inhibitors like sunitinib, sorafenib, and bevacizumab.
  • To introduce emerging VEGF inhibitors and discuss treatment strategies.

Main Methods:

  • Review of major clinical trials (Phase III) for VEGF inhibitors.
  • Analysis of efficacy, progression-free survival, and quality of life data.
  • Summary of side effects, toxicities, and therapeutic combinations.

Main Results:

  • Novel VEGF pathway inhibitors show significant clinical benefit in advanced renal cancer.
  • Established agents like sunitinib, sorafenib, and bevacizumab have demonstrated efficacy.
  • Ongoing research explores new VEGF inhibitors and combination therapies.

Conclusions:

  • VEGF pathway inhibitors represent a major advancement in treating advanced renal cancer.
  • These targeted therapies offer improved outcomes compared to traditional treatments.
  • Further research is essential for optimizing sequential and combination therapeutic approaches.

More Related Videos

Intravascular Delivery of Biologics to the Rat Kidney07:29

Intravascular Delivery of Biologics to the Rat Kidney

Published on: September 1, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.